DE60000133T2 - Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen - Google Patents

Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen

Info

Publication number
DE60000133T2
DE60000133T2 DE60000133T DE60000133T DE60000133T2 DE 60000133 T2 DE60000133 T2 DE 60000133T2 DE 60000133 T DE60000133 T DE 60000133T DE 60000133 T DE60000133 T DE 60000133T DE 60000133 T2 DE60000133 T2 DE 60000133T2
Authority
DE
Germany
Prior art keywords
fatty acids
essential fatty
dha
epa
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60000133T
Other languages
English (en)
Other versions
DE60000133D1 (de
DE60000133C5 (de
Inventor
Franco Pamparana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11381919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60000133(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of DE60000133D1 publication Critical patent/DE60000133D1/de
Publication of DE60000133T2 publication Critical patent/DE60000133T2/de
Application granted granted Critical
Publication of DE60000133C5 publication Critical patent/DE60000133C5/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60000133.4T 1999-02-17 2000-02-07 Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen Expired - Lifetime DE60000133C5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI990313 1999-02-17
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
PCT/EP2000/000957 WO2000048592A1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events

Publications (3)

Publication Number Publication Date
DE60000133D1 DE60000133D1 (de) 2002-05-23
DE60000133T2 true DE60000133T2 (de) 2002-11-21
DE60000133C5 DE60000133C5 (de) 2014-02-27

Family

ID=11381919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60000133.4T Expired - Lifetime DE60000133C5 (de) 1999-02-17 2000-02-07 Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen

Country Status (26)

Country Link
US (2) US7462643B1 (de)
EP (2) EP1247523A1 (de)
JP (2) JP5441287B2 (de)
KR (2) KR100823051B1 (de)
CN (1) CN1230159C (de)
AT (1) ATE216230T1 (de)
AU (1) AU775078B2 (de)
BR (1) BR0008153A (de)
CA (1) CA2362271C (de)
CZ (1) CZ301307B6 (de)
DE (1) DE60000133C5 (de)
DK (1) DK1152755T3 (de)
EA (1) EA004312B1 (de)
ES (1) ES2174814T3 (de)
HK (1) HK1044720B (de)
HU (1) HUP0200111A3 (de)
ID (1) ID30205A (de)
IL (2) IL144377A0 (de)
IT (1) IT1308613B1 (de)
NO (1) NO328797B1 (de)
NZ (1) NZ513093A (de)
PL (1) PL209078B1 (de)
PT (1) PT1152755E (de)
SK (1) SK286523B6 (de)
WO (1) WO2000048592A1 (de)
ZA (1) ZA200106029B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
CA2485116C (en) 2002-05-03 2013-02-05 Pronova Biocare As Use of epa and dha in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
DK1863570T3 (da) 2005-03-11 2011-06-20 Recon Oil Ind Private Ltd Synergistisk varmestabilt oliemedium med eicosapentaensyre (EPA) og decosahexaensyre (DHA)
KR101465717B1 (ko) * 2005-07-08 2014-12-01 모치다 세이야쿠 가부시키가이샤 심혈관 이벤트 발병 예방용 조성물
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
NZ569676A (en) * 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
CA2571462C (en) 2006-02-07 2013-08-13 Mochida Pharmaceutical Co., Ltd. Composition for preventing recurrence of stroke
CA2653787C (en) 2006-05-31 2016-06-21 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
CN102149376B (zh) * 2008-08-07 2013-12-25 Spa抗菌素产品公司 症状性心力衰竭的长期治疗
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
EP2475309A4 (de) * 2009-09-08 2015-07-29 Atrium Medical Corp Herniapflaster
JP5872483B2 (ja) 2009-12-30 2016-03-01 ビーエイエスエフ ファーマ（コーラニッシュ）リミテッド 擬似移動床式クロマトグラフ分離方法
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
KR101681907B1 (ko) * 2012-02-27 2016-12-12 주식회사 케어사이드 혈액 순환 촉진 및 피부 질환 개선용 조성물
EP3072510B1 (de) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3-fettsäureesterzusammensetzungen
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
WO2014057362A2 (en) * 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP3118186B1 (de) 2013-12-11 2022-02-09 Novasep Process Chromatografische anlage zur herstellung von mehrfach ungesättigten fettsäuren
EP3092218B1 (de) 2014-01-07 2022-03-09 Novasep Process Solutions Verfahren zur reinigung von aminosäuren
PL237374B1 (pl) * 2017-11-10 2021-04-06 Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
NO157302C (no) 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
JP2893866B2 (ja) 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5324323A (en) 1992-09-09 1994-06-28 Telectronics Pacing Systems, Inc. Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
WO1994013642A1 (de) 1992-12-11 1994-06-23 Ciba-Geigy Ag Substituierte benzazepinone
CN1082909A (zh) * 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH07118229A (ja) 1993-10-19 1995-05-09 Fujisawa Pharmaceut Co Ltd 尿素誘導体およびその製造法
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) 1994-06-30 1996-01-16 Fujirebio Inc 虚血性心疾患治療剤
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
EA199900261A1 (ru) 1996-09-05 1999-10-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Генная терапия застойной сердечной недостаточности
US6313167B1 (en) 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1130027A1 (de) 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
JP2002537252A (ja) 2002-11-05
HUP0200111A3 (en) 2003-03-28
AU775078B2 (en) 2004-07-15
EP1152755B1 (de) 2002-04-17
NZ513093A (en) 2003-02-28
PL350851A1 (en) 2003-02-10
BR0008153A (pt) 2001-11-06
IT1308613B1 (it) 2002-01-09
CN1343120A (zh) 2002-04-03
EA004312B1 (ru) 2004-02-26
SK10802001A3 (sk) 2001-12-03
WO2000048592A1 (en) 2000-08-24
ZA200106029B (en) 2002-09-25
CA2362271C (en) 2008-07-15
SK286523B6 (sk) 2008-12-05
CZ20012947A3 (cs) 2002-04-17
EP1247523A1 (de) 2002-10-09
NO20013938L (no) 2001-08-14
NO20013938D0 (no) 2001-08-14
NO328797B1 (no) 2010-05-18
KR20010102183A (ko) 2001-11-15
PT1152755E (pt) 2002-09-30
HK1044720A1 (en) 2002-11-01
JP2010116414A (ja) 2010-05-27
EA200100895A1 (ru) 2002-02-28
DE60000133D1 (de) 2002-05-23
US20090018193A1 (en) 2009-01-15
ES2174814T3 (es) 2002-11-16
US7462643B1 (en) 2008-12-09
PL209078B1 (pl) 2011-07-29
AU2907500A (en) 2000-09-04
KR20070098954A (ko) 2007-10-05
EP1152755A1 (de) 2001-11-14
CN1230159C (zh) 2005-12-07
DE60000133C5 (de) 2014-02-27
DK1152755T3 (da) 2002-07-22
HK1044720B (zh) 2006-08-18
KR100823051B1 (ko) 2008-04-18
JP5441287B2 (ja) 2014-03-12
IL144377A0 (en) 2002-05-23
CZ301307B6 (cs) 2010-01-06
CA2362271A1 (en) 2000-08-24
ATE216230T1 (de) 2002-05-15
IL144377A (en) 2006-12-10
ID30205A (id) 2001-11-15
HUP0200111A2 (hu) 2002-05-29
ITMI990313A1 (it) 2000-08-17

Similar Documents

Publication Publication Date Title
DE60000133T2 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
ATE236627T1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
YU59303A (sh) Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca
ATE315388T1 (de) Therapeutische kombinationen von fettsäuren
ES2117390T3 (es) Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
DK0623019T3 (da) Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
EP0302481A3 (de) Verwendung von freien Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von Diabetes mellitus
HUP0000419A2 (hu) Eikozapentaénsavat és/vagy sztearidonsavat tartalmazó gyógyászati készítmény
TH58453B (th) การบำบัดของกรดไขมัน
RU94002318A (ru) Триглицериды

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA ITALIA S.P.A., MAILAND/MILANO, IT

8364 No opposition during term of opposition
8310 Action for declaration of annulment